These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 25495002

  • 1. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
    Ektare VU, Lopez JM, Martin SC, Patel DA, Rupnow MF, Botteman MF.
    Am J Manag Care; 2014 Oct; 20(10 Suppl):S204-15. PubMed ID: 25495002
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G, Lavalle-González FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R, Canovatchel W.
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [Abstract] [Full Text] [Related]

  • 5. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
    Bailey RA, Vijapurkar U, Meininger G, Rupnow MF, Blonde L.
    Clin Ther; 2015 May 01; 37(5):1045-54. PubMed ID: 25795432
    [Abstract] [Full Text] [Related]

  • 6. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    Bailey RA, Damaraju CV, Martin SC, Meininger GE, Rupnow MF, Blonde L.
    Am J Manag Care; 2014 Jan 01; 20(1 Suppl):s16-24. PubMed ID: 24512193
    [Abstract] [Full Text] [Related]

  • 7. Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
    Ferrario MG, Lizán L, Montagnoli R, Ramírez de Arellano A.
    Prim Care Diabetes; 2016 Jun 01; 10(3):220-6. PubMed ID: 26546244
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD, Pérez Belmonte LM, Suárez Tembra M, Olalla Sierra J, Gómez Huelgas R.
    Diabetes Metab; 2018 Sep 01; 44(4):373-375. PubMed ID: 29859992
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M.
    Diabetes Obes Metab; 2016 Aug 01; 18(8):812-9. PubMed ID: 27160639
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.
    Diabetes Obes Metab; 2008 Jun 01; 10 Suppl 1():43-55. PubMed ID: 18435673
    [Abstract] [Full Text] [Related]

  • 11. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
    Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L.
    Am J Manag Care; 2014 Dec 01; 20(13 Suppl):s296-305. PubMed ID: 25734218
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.
    Endocr Pract; 2018 Mar 01; 24(3):273-287. PubMed ID: 29547044
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug 01; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.